PDF电子书：The Delivery of Regenerative Medicines and Their Impact on Healthcare

zsg

5 U( N) l# ?6 n+ T9 W

( }6 z5 n( m! _1 u" p2 l, EThe Delivery of Regenerative Medicines and Their Impact on Healthcare' X" u7 y: L/ U$ @
Edited by
9 a3 s, K6 s& ^7 FDr. Catherine D. Prescott
& x! Y" Z$ B/ a7 N. M$ LProfessor Dame Julia Polak' H4 l- d5 Q6 v. M" p+ q

% R  O' U7 u( {  J$ C4 I" UContents6 ]" L) p* A/ A* \+ g
Foreword...................................................................................................................vii, t3 }3 U, M$ Y- g- c$ m9 r
Preface.......................................................................................................................ix  T  J! \8 }( q' o  f2 k6 d
Acknowledgments......................................................................................................xi$ t/ j# ?, i9 D7 l
About the Editors.................................................................................................... xiii2 X: ^9 G- Z: s* b/ k6 t6 |3 @) g
Contributors..............................................................................................................xv
, T3 m$ `- n, Z7 M2 \/ L% lSection 1 I ntroduction: C$ _/ t: B) A3 R" o; M1 ]
Chapter 1 What Is Regenerative Medicine?...........................................................3+ d, r; c3 h5 |) D$ f! a' j
Julia M. Polak
8 M, E9 y. u: \$ cSection 2 Finance  f7 j" ]% S7 k+ E4 t6 U
Chapter 2 A New Political–Financial Paradigm for Medical Research:- w; s9 K7 N, S6 O& z; d! |2 g  G
The California Model?........................................................................ 11
/ v' ^; t" _, L6 h" I  f9 H% h) ^Robert N. Klein and Alan Trounson# M; \7 C3 Y6 c5 e4 ]
Chapter 3 Investment Models: Public Funding in Australia................................ 35& @; e+ [( Q. u* A8 Y& i+ W
Graham Macdonald$ T1 |4 \# y0 t7 v/ [" q
Chapter 4 Canada: Capitalizing on a 50-Year Legacy......................................... 43
5 u7 i' |- A; Q( r9 j: p/ NAndrew Lyall+ }/ p; f: |$ l+ o7 w& I+ @" ~
Chapter 5 Investing in Regenerative Medicine: What Drives Private Investors?.... 594 U. Z9 Q. w  s" y6 G" [. R4 z$ P
Catherine D. Prescott
* D9 k3 W$ V" p* ?$ }+ ZChapter 6 Public Investment Models: Coming out of the Closet and
; Q$ N; n& |" n8 N! C; o0 w6 w2 iGoing Public!...................................................................................... 67
  W3 ]- {" ]$ e( VReni Benjamin
$ W* m! F% |6 j; w: k1 ASection 3 Business Models
5 e" Y6 G2 H1 p( e. N& RChapter 7 Cell-Based Products: Allogeneic.........................................................85. X& N: [9 I1 L8 d9 S7 m
Paul Kemp4 z: W( n+ Q- {, W
Chapter 8 Autologous Cell-Based Products: Fulfilling the Promise of! W- H2 c4 h5 z4 P/ F8 Y6 h4 x
Cell Therapy........................................................................................97' H! D$ o* z6 i$ R5 U% T2 g1 l( x
Eduardo Bravo and Magdalena Blanco-Molina$ ]# e! E  X& P, v+ }; j, M
Chapter 9 Business Models for Cord Blood....................................................... 1171 n) P: o; t2 f- ~2 B0 l" ~9 u
Suzanne M. Watt9 }' L) z/ g6 P
Chapter 10 Changing the Game of Drug Discovery............................................ 131
' `! s, T# X) I4 l, EJohn Walker) [5 R* X( i4 m2 T4 _( L/ u8 ?6 Q
Chapter 11 Discovery of Small Molecule Regenerative Drugs........................... 141
* {% f6 {/ w! j2 PYen Choo
9 W; T# O5 R, v6 S# kChapter 12 Adoption of Therapeutic Stem Cell Technologies by Large
, a" z9 p2 F) f7 @) q* TPharmaceutical Companies............................................................... 153; o6 P/ N5 o% |! v3 d6 a; j5 E
Alain A. Vertès
1 u1 c* z1 u0 `3 UChapter 13 Role of Tool and Technology Companies in Successful" J+ U' m9 b% c$ z) w6 s
Commercialization of Regenerative Medicine.................................. 177
* F/ l0 [8 s3 ], x1 s" ?: NJoydeep Goswami and Paul Pickering
+ B7 V8 D' |: p. p2 [8 P0 C% e/ Z, u  rChapter 14 Key Considerations in Manufacturing of Cellular Therapies........... 189
9 |- R3 J3 u7 u8 [# }* E: S/ ?# r7 pRobert A. Preti
0 c' \+ E$ N4 k% ~" N# b) EChapter 15 State of the Global Regenerative Medicine Industry........................ 213/ P' q+ G! ^6 O+ m: Y0 w5 `
R. Lee Buckler, Robert Margolin, and Sarah A. Haecker
* x2 r( u+ f/ X0 JSection 4 Intellectual Property" [8 S7 G) {- c7 i6 [1 U
Chapter 16 Regenerating Intellectual Property: Europe after WARF................. 239: O/ z. `- B$ d* L1 G3 g
Julian Hitchcock and Devanand Crease
5 ]7 o/ \+ x& J5 ~Chapter 17 Protecting Regenerative Medicine Intellectual Property in the# V! [( R. v# G2 v* s; _4 e* a
United States: Problems and Strategies............................................. 257
, s2 k4 _0 N: ?3 O% iDavid Resnick, Ronald I. Eisenstein, and Joseph M. McWilliams
8 X+ p% U) a5 u6 l0 z% D7 kChapter 18 Impacts of Indian Policies and Laws on Regenerative3 X# C' h) t2 I6 \$ W. D; k3 Y
Medicine Patent Applications........................................................... 281
2 a- ]& F, ^5 V3 S/ b/ b8 |Prabuddha Ganguli* f5 V% P( j) }- I# x
Section 5 Regulatory Landscape  u) N, D1 i. N9 M/ M
Chapter 19 A CATalyst for Change: Regulating Regenerative Medicines in1 ]- C5 S4 M# C+ |1 f/ v" p
Europe...............................................................................................295
# y( Q5 e: J7 z; p( B' R8 t9 k7 aChristopher A. Bravery) n* w8 D. |4 X2 t+ r' @& l
Chapter 20 United States Regulatory Reimbursement, Political
- i8 }4 L  S& C$ ]Environment, and Strategies for Reform........................................... 323  h6 S; F; L4 E2 g  r' F  t4 B; j$ R
Michael J. Werner
0 l6 s- {; H8 U( KSection 6 Reimbursement0 _# w/ K/ I  C/ [9 D* [
Chapter 21 The Fourth Hurdle: Reimbursement Strategies for) |5 I) Z4 c' s. O( W( L( U  a
Regenerative Medicine in Europe..................................................... 3378 ]; A- t0 A% Q" T
François M. Meurgey and Micheline Wille+ _! p- r  }/ C$ |* U0 q6 p
Chapter 22 Cellular Therapies and Regenerative Medicine: Preparing for5 x* N  r3 F9 v0 p. _5 _1 b% i
Reimbursement in the United States................................................. 351
2 R% ~2 F: v+ \3 ?+ p0 O& a: iEric Faulkner
& M% l' N2 _* V+ W3 v4 hChapter 23 Adoption and Evaluation of Regenerative Medicine and the0 v$ u9 m& v" T" F9 Q* f  A& f$ Q2 U5 m
National Health Service....................................................................369, K( t1 t3 N2 z, g
Margaret Parton) y" ?% j/ ^9 W
Section 7 I nsurance and Risk Management
! O- R' q. M% w! F) q# X. sChapter 24 Role of Insurance: If You Build It, Will They Insure It?.................. 379
: t! `7 ?$ W7 }; u8 U# T7 H$ [Matthew Clark/ E% s3 V/ g0 W! ]& X7 q) I- Q/ j
Index....................................................................................................................... 3915 W- u9 L; @$ `
/ l9 O* b5 p; t) v5 {* I# F0 N
[hide][/hide]

henryjia

thank you

beautylive

不错不错,我喜欢看  

yukun

哎 怎么说那~~  

命运的宠儿

这个贴好像之前没见过  

不倒翁

先看看

tempo

不错不错,我喜欢看  

haha3245

干细胞研究还要面向临床

123456zsz

快毕业了 希望有个好工作 干细胞还是不错的方向

依旧随遇而安

慢慢来，呵呵